Preemptive HMG-CoA reductase inhibition provides graft-versus-host disease protection by Th-2 polarization while sparing graft-versus-leukemia activity
about
European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemiaTreatment of dyslipidemia in allogeneic hematopoietic stem cell transplant patientsCurrent and emerging strategies for the prevention of graft-versus-host diseaseThe proteomic to biology inference, a frequently overlooked concern in the interpretation of proteomic data: a plea for functional validation.Donor statin treatment protects against severe acute graft-versus-host disease after related allogeneic hematopoietic cell transplantation.Impact of recipient statin treatment on graft-versus-host disease after allogeneic hematopoietic cell transplantation.Statin drug interactions and related adverse reactions.α-1-Antitrypsin (AAT)-modified donor cells suppress GVHD but enhance the GVL effect: a role for mitochondrial bioenergetics.The effect of statins on mortality in septic patients: a meta-analysis of randomized controlled trials.The association between donor and recipient statin use and infections after allogeneic hematopoietic cell transplantation.Atorvastatin Improves Inflammatory Response in Atherosclerosis by Upregulating the Expression of GARP.Low doses of natural killer T cells provide protection from acute graft-versus-host disease via an IL-4-dependent mechanismDeficiency of CD73/ecto-5'-nucleotidase in mice enhances acute graft-versus-host diseasePathogenesis of acute graft-versus-host disease: from intestinal microbiota alterations to donor T cell activation.Tipifarnib-mediated suppression of T-bet-dependent signaling pathways.Atorvastatin for the Prophylaxis of Acute Graft-versus-Host Disease in Patients Undergoing HLA-Matched Related Donor Allogeneic Hematopoietic Stem Cell Transplantation (allo-HCT).Approaches for the prevention of graft-versus-host disease following hematopoietic cell transplantationPreclinical models of acute and chronic graft-versus-host disease: how predictive are they for a successful clinical translation?The Nlrp3 inflammasome regulates acute graft-versus-host disease.Hyperlipidemia and statin use after allogeneic hematopoietic stem cell transplantation.Sibling donor and recipient immune modulation with atorvastatin for the prophylaxis of acute graft-versus-host disease.Regulation of different inflammatory diseases by impacting the mevalonate pathway.IL-21 blockade reduces graft-versus-host disease mortality by supporting inducible T regulatory cell generation.High pre-transplant serum nitrate levels predict risk of acute steroid-refractory graft-versus-host disease in the absence of statin therapy.Transcriptional regulation of the mucosal immune system mediated by T-bet.Immunoregulation of GVHD by triggering the innate immune system with CpG.The evolving role of statins in hematopoietic stem and progenitor cell transplantation.Antileukemic properties of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors.Helper T-cell differentiation in graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.Blocking LFA-1 activation with lovastatin prevents graft-versus-host disease in mouse bone marrow transplantation.Lovastatin inhibits T-cell proliferation while preserving the cytolytic function of EBV, CMV, and MART-1-specific CTLsA randomized trial of direct pulp capping in primary molars using MTA compared to 3Mixtatin: a novel pulp capping biomaterial.Inhibition of protein geranylgeranylation and farnesylation protects against graft-versus-host disease via effects on CD4 effector T cells.Simvastatin induces Foxp3+ T regulatory cells by modulation of transforming growth factor-beta signal transduction.Graft-versus-host disease: suppression by statins.Clinical risk factors for adverse events in allopurinol users.Immune modulatory effects of statins.Spleen tyrosine kinase (Syk) is a potent target for GvHD prevention at different cellular levels.Incidence of type 2 diabetes mellitus and hyperlipidemia in patients prescribed dasatinib or nilotinib as first- or second-line therapy for chronic myelogenous leukemia in the US.Statin effects on regulatory and proinflammatory factors in chronic idiopathic urticaria.
P2860
Q26749324-BC1E2FBF-59C2-4310-B16A-32A21177119DQ26996051-013A081E-6047-4671-818A-77A440CE4B3FQ27016541-21966393-A463-49DB-BB45-D252A83F227BQ30700824-899C61EA-B6D9-4245-BF39-07122E891959Q33677489-4B01894C-DD44-48C4-8A42-78B464D35912Q34106362-DED577C3-AE32-4455-AA88-448FDBA85BF9Q34292468-76F53D34-CFD8-4460-B36A-E7CA30057976Q34431458-8F16B574-5077-4629-B1D6-C7205A501E8CQ35082349-E099896E-256B-47CE-9342-27D1650EC067Q35152144-FED2AFD3-F809-4293-B005-7F6CABD54E6CQ35639525-A2F33579-CEED-4F2B-B207-9245180DF36CQ35866143-34891FF1-833E-4921-89C8-C34A1FFF2D39Q35995245-71A524FC-CAE9-4184-B060-ACE45E9947E7Q36130498-E6F5A1B4-C02C-49C0-84E7-AA2E8354B56EQ36181770-3CD57617-7A31-4190-BEE4-BED032212554Q36445685-B1CB5877-F02A-4C5E-B5CC-8471ABE8FB03Q36891433-349FF8CE-5B5A-428F-AE22-ED305EB6B306Q37035815-A3372700-F683-499F-80C1-B9BA8ED9280AQ37194967-26918BC4-8D8A-4F8A-9FA4-A51762C5FD4DQ37247613-16488961-3833-4008-996D-ECC0FF4E9AC5Q37348628-39D8D7CA-F57A-49C1-BE12-895413EA7917Q37385042-C94CF25A-4344-42E9-8185-AE43DA44FCB7Q37484523-B00EA408-3B86-4F1D-9C43-C6845C6D95EDQ37618927-B473E818-3AAA-45B7-BA31-9D70AD6FC7ACQ37789145-7714C2B3-06E2-4AB7-B4F2-905728180AC3Q37810081-ADA3021D-75E8-4D6D-BA01-3DB3CAF337E0Q37995193-950590A3-1EE7-481B-AD46-8492518BC76BQ38094203-D238D8AA-A85E-47AF-BB71-36E7D94B94A5Q38202009-BF8DB976-4A2F-41D8-87CC-BAF9FCADB946Q39559416-D08C571D-FE0D-433E-9D89-B51A6CFACBD1Q39847298-98FA173A-1605-4709-8701-F3E0D7BF3F82Q40539552-AFEDDFF7-C1A6-467F-BD0D-E5C500771C7CQ42453294-32439926-5C22-4F9F-A76A-04539132432FQ43090511-70F22A28-B2DF-4C0A-9F3F-365A9E59934BQ43780095-FD89B1DB-D654-4D45-8B57-D162B63A4FDEQ45127731-2AF31205-2E49-4C6C-830C-12F6D220E596Q50214328-84521F31-081D-4CE9-B17C-4EBB6A495DA7Q52621229-2285C239-5B7A-416A-BD30-DA80C1B76623Q52820899-2AE39E2D-F251-446C-AE03-2925D88A3340Q53213843-E8FD098B-98E8-40B5-9947-E5CB787C5987
P2860
Preemptive HMG-CoA reductase inhibition provides graft-versus-host disease protection by Th-2 polarization while sparing graft-versus-leukemia activity
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Preemptive HMG-CoA reductase i ...... graft-versus-leukemia activity
@ast
Preemptive HMG-CoA reductase i ...... graft-versus-leukemia activity
@en
type
label
Preemptive HMG-CoA reductase i ...... graft-versus-leukemia activity
@ast
Preemptive HMG-CoA reductase i ...... graft-versus-leukemia activity
@en
prefLabel
Preemptive HMG-CoA reductase i ...... graft-versus-leukemia activity
@ast
Preemptive HMG-CoA reductase i ...... graft-versus-leukemia activity
@en
P2093
P2860
P1433
P1476
Preemptive HMG-CoA reductase i ...... graft-versus-leukemia activity
@en
P2093
Jeanette Baker
Lawrence Steinman
Neeraja Kambham
Robert S Negrin
Robert Zeiser
Sawsan Youssef
P2860
P304
P356
10.1182/BLOOD-2007-08-106005
P407
P577
2007-09-07T00:00:00Z